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Abstract 
 
Sample size calculation is a crucial step in all experimental design.  In clinical 
research and drug development activities, it is required in order to be able to 
demonstrate a presumed statistical effect of a drug or a treatment. Today many sample 
size calculation algorithms and formulas exist. However, in this work an algorithm 
based on the results of Liu and Liang (1997) is tested and used to predict the right 
sample size based on data from a study involving 211 patients with abdominal aortic 
aneurysm (also known as AAA). In this study the growth of the diameter of the 
aneurysm was monitored over time and the slope of that growth was calculated. Since 
no information about treatment effect was provided, a statistically significant 
reduction of the slope by 20% was chosen to replace the lack. More precisely, we 
want to calculate the sample size required to demonstrate a desired effect of growth 
reduction by 20% of a treatment at the statistical power of 80%.   
 
The aim of this work was not only to examine statistically the abdominal aortic 
aneurysm data from placebo patients and the involved variables but also to evaluate 
the “longpower” package existing in the programming language R to calculate the 
sample size for longitudinal data. 
  
The statistical model chosen for this work was a linear mixed model with TIME as a 
random and fixed variable and logarithm of aneurysm diameter at baseline (AD0) as a 
fixed variable. Non-equidistant TIME measured the intervals of ultrasound screenings 
in years whereas AD0 was measured in mm. 
 
The formula of Liu and Liang (1997) using “longpower” package in R computed a 
required sample size of 420 patients with a power of 80% and reduction of TIME 
slope by 20%. In order to verify the sample size of 420 a simulation for the control 
and the treatment groups were run. A two-sample t-test showed statistically 
significant difference in means of logarithms of aneurysm diameters for simulated 
control and treatment groups at the significance level of less than 0.1%. 
 
Moreover, a linear mixed model using simulated data for 210 placebo and 210 
treatment patients to investigate a cross effect of TIME*TREATMENT as fixed and 
random variable gave a statistically significant difference between the control and the 
treatment groups at the significance level of less than 0.1%. 
 
To test the number 2*210 patients, another simulation of 2*105 patients were run. 
Two-sample t-tests showed statistically significant difference in means of logarithms 
of aneurysm diameters for these simulated control and treatment groups at the 
significance level of less than 0.1%. Investigation of the cross effect of 
TIME*TREATMENT in a linear mixed model showed statistically significance at the 
significance level of less than 0.1% for the simulation of 2*105 patients.  
 
Although both sample sizes of 2*210 and 2*105 were acceptable from statistical 
standpoint, power calculations revealed that the sample size of 2*210 gave a power of 
73% whereas 2*105 gave only a power of 61%. Finally, the sample size of 420 
(2*210) was verified by the simulations. 
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Background 
 
Sample size calculation 
 
Prior to designing experiments researchers must know what sample size they should 
choose to be able to demonstrate a desired effect of a medication or a treatment. Over 
the course of many years, many different methods and formulas have been developed 
for this purpose. One of these formulas is Liu and Liang’s formula (1997) [3] which is 
implemented in the “longpower” package of the programming language R. The 
formula is suited for studies for longitudinal data at equidistant points in time with 
correlated observations. This function will be applied to abdominal aortic aneurysm 
data containing non-equidistant measurements for patients who have been ultrasound 
screened several times over a period of time. 
 
Abdominal aortic aneurysm 
 
Abdominal aortic aneurysm (also known as AAA) is a localized dilatation of the 
abdominal aorta exceeding the normal diameter by more than 50 percent (normal 
diameter of the aorta is approximately 20 mm). Mostly, AAA causes no symptoms 
while it can sometimes cause pain in the abdomen and back. The most dangerous 
complication of abdominal aortic aneurysms is the rupture of the aneurysm which 
spills a large amount of blood into the abdominal cavity and can lead to death within a 
few minutes (See Figure 1). 
 
 
 
Figure 1: A CT image of an AAA (34 mm in diameter). The red arrow indicates the 
position of the aneurysm [8]. 
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So far no medication to decrease the growth rate or rupture rate of asymptomatic 
AAA has been found. However, studies have suggested that therapy with angiotensin 
converting enzyme inhibitors, beta-blockers, and statins can protect against AAA. 
Ultimately surgery is needed for a severe (>55 mm in diameter) AAA. 
Linear mixed model 
 
A linear mixed model is a linear statistical model containing both fixed and random 
effects, i.e. mixed effects. Such models are frequently used for statistical analysis and 
are especially useful when repeated measurements are made on the same person or 
statistical unit. 
 
A mixed model in matrix notation can be generally represented as: 
 
Y = Xβ + ZU + ε 
 
Y is a vector of observations, with mean E(Y) = Xβ 
β is a vector of fixed effects 
U is a vector of random effects with mean E(U) = 0 and variance-covariance matrix 
 Var(U) = G 
ε is a vector of random error terms with mean E (ε) = 0 and variance Var(ε) = R 
X and Z are matrices of regressors relating Y to β and U 
 
Nevertheless, the linear mixed model in this work will be represented as: 
 
Yij = αi,fixed + αi,random + βi,fixedXij + βi,randomZij + εij   
 
Yij is a matrix of dependent variable 
Xij are matrices of fixed independent variables  
Zij are matrices of random independent variables   
αi,fixed is intercept with a fixed part (within the group)  
αi,random is intercept with a random part (within the individual) ~ N (0, σintercept
2
) 
βi,fixed is slope with a fixed part 
βi,random is slope with a random part ~ N (0, σslope
2
) 
εij are random error terms ~ N (0, σerror
2
) 
i is individual 
j is time 
 
Longpower 
 
The “longpower” package contains functions for computing sample size for linear 
models of longitudinal data based on the formula of Liu and Liang (1997) and Diggle 
et al. (2002) [5]. 
 
In this work the formula of Liu and Liang (1997) was chosen to calculate the sample 
size with a given effect for the linear mixed model.   
 
This is a powerful package since not so many packages which can calculate sample 
size over a time period with different measurements exist in R. One drawback of the 
functions of “longpower” is their inability to handle non-equidistant points. 
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Results 
 
Studied variables 
 
To set up our statistical linear mixed model potential variables needed to be chosen. 
The pharmaceutical data provided the following variables: 
 
Variable Description 
SUBJECT Identification number for each patient 
RANGE Range of the aneurysm depending on size at baseline 
25<=AD0<35 
35<=AD0<45 
45<=AD0<55 
         AD0=>55 
AD Aneurysm diameter 
AD0 Aneurysm diameter at baseline 
TIME Time for each measurement 
WOMAN Gender 
DIABETES Occurrence of diabetes type 2 
AGE Age 
 
Table 1: A summary of the variables assumed to be involved in abdominal aortic 
aneurysm and the response variable (AD). 
 
The study started to assess which of these variables to be included in or excluded from 
the model. So a series of linear mixed model separately for each variable were run in 
SPSS for this purpose. RANGE, WOMAN, DIABETES and AGE gave high p-values 
(much greater than 0.05) and were excluded from the model. It was unexpected that 
WOMAN was not statistically significant at the significance level of 5% despite the 
fact that the vast majority of the patients were men. An attempt to categorize the 
patients according to their age was done with no success of getting an acceptable p-
value. 
 
Test the model 
 
Only the variables AD0 (Aneurysm diameter at baseline) and TIME were statistically 
significant at the significance level of 5%. So a linear mixed model with TIME as 
fixed and random variable and AD0 as fixed was run. TIME was chosen as a random 
variable to let a variation in time between the individuals.  
 
The covariance structure chosen here after referring to Littell et al. (2000, [4]) was the 
default one in SPSS i.e. Variance Components. The reason for the choice was that 
Variance Components does not need a repeated variable which was lacked in the 
provided data. In addition Variance Components assumes no special correlation 
structure between the measurements which was appropriate for our data since the 
measurements were not equidistant in time.  
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Moreover logarithmation of AD and AD0 gave much better Information Criteria 
which made us to use the logarithms of these variables in the rest of the study.  
 
Variables Schwarz’s Bayesian Criterion (BIC) 
AD and AD0 5106.096 
LOG10_AD and LOG10_AD0 -5014.007 
 
Table 2: The Information Criteria obtained when running the model with AD and 
AD0 respective LOG10_AD and LOG10_AD0. The lower the BIC value the better the 
model is. 
 
To evaluate the model the residuals were plotted (Figure 2). As shown the model did 
not show heteroscedasticity and the residuals seemed normally distributed. 
 
  
 
Figure 2: Plotted residuals for the model with dependent variable Log10 _AD and 
independent variables TIME and Log10_AD0. 
 
Growth rate 
 
 
Figure 3: The growth rate of AAA for the patients in the data. For every year the 
aneurysm grew in average 1.74 mm. 
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The growth rate of the aneurysm was studied in this group of patients by plotting 
TIME against ADJUSTED_AD which was simply the difference of AD and AD0. 
According to Figure 3 for each passed year the aneurysm grew 1.74 mm in average 
for these patients. 
 
The model 
 
By choosing TIME as random and fixed variable and Log10_AD0 as fixed, the 
following results were obtained in SPSS. 
 
Estimates of Fixed Effects
a
 
Parameter Estimate Std. Error df t Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
Intercept ,023364 ,022676 282,710 1,030 ,304 -,021271 ,067998 
TIME ,023846 ,001450 153,547 16,445 ,000 ,020981 ,026710 
LOG10_AD0 ,983406 ,014362 280,894 68,474 ,000 ,955135 1,011676 
a. Dependent Variable: Log10 of aneurysm diameter. 
 
Table 3: The fixed parameter estimates of the linear mixed model. 
 
Estimates of Covariance Parameters
a
 
Parameter Estimate Std. Error Wald Z Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
Residual ,000323 1,626686E-005 19,838 ,000 ,000292 ,000356 
Intercept [subject = SUBJECT] Variance ,000130 2,388897E-005 5,436 ,000 9,055928E-005 ,000186 
TIME [subject = SUBJECT] Variance ,000300 4,173999E-005 7,180 ,000 ,000228 ,000394 
a. Dependent Variable: Log10 of aneurysm diameter. 
 
Table 4: The random variance estimates of the linear mixed model. 
 
No interaction between TIME and Log10_AD0 as fixed variables was defined since 
TIME started at 0 when measuring AD0. 
 
Our model was defined as: 
Log10_AD = αfixed + αrandom + β1fixedTIME + β1randomTIME + β2fixedLog10_ AD0 + ε 
 
i.e. according to Tables 3 and 4: 
 
Log10_AD = 0.023364 + √         Z1 + 0,023846 TIME + √         Z2 TIME  
 + 0,983406 Log10_ AD0 + √         Z3 
 
where Z1, Z2 and Z3 were independent random variables distributed N (0,1). 
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Run “longpower” 
 
“longpower” is a package defined in the programming language R and from this point 
we stopped using SPSS and the statistical analysis was transferred to R. 
 
Since the data contained only placebo patients and no treatment patients, a strategy of 
reduction of TIME slope by 20% was used instead. This strategy just implied that the 
reaching time to the rupture point of 55 mm for the patients was assumed to be 
delayed by 20%. 
 
Correlation between random intercept and random slope was assumed to be 0 since 
data about treatment patients was not available. To test this correlation namely 0, 
different values were inserted in the variable of correlation without changing the 
sample size significantly. This fact indicated that the correlation between random 
intercept and random slope was not so important for this data and this model. 
 
Moreover, to assess the number of measurements for the placebo group, the 
equidistant time t’ until the rupture of aorta in the placebo data was calculated 
according to: 
 
Log10_AD = 0.023364 + 0,023846 TIME + 0,983406 Log10_ AD0  
 
Log10(55) = 0.023364 + 0,023846 * t’ + 0,983406 * 1.5702    → t’ = 7.2 years 
 
Here 55 mm is the assumed rupture point and 1.5702 is the mean of Log10_AD0 in 
the placebo data. 
 
In addition, two plots were drawn for a control and a treatment patient to assess the 
number of measurements for the treatment group in “longpower”. As shown in Figure 
4, the control patient passed the rupture line (AD = 55 mm or Log10_AD = 1.74) after 
approximately 8 years whereas the treatment patient passed the same line after 
approximately 10 years. 
 
Figure 4: The black dots show the control patient to pass the rupture line (red) after 8 
years whereas the green dots, with a slope reduction of 20%, show the treatment 
patient passing the same line after 10 years. 
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So, 10 equidistant measurements for the pretended treatment group were assumed. 
The difference of the slopes of these plots gave the most crucial argument delta in 
“longpower”. 
 
“longpower” is a straight-forward algorithm [1,3] and only needs to be inserted with 
the input values. Input arguments in “longpower” are presented in Table 5. 
 
Argument Description 
N the total sample size 
n sample size per group 
delta group difference (possibly a vector of differences) 
u a list of covariate vectors or matrices associated with the parameter of interest 
v a list of covariate vectors or matrices associated with the nuisance parameter 
sigma2 the error variance 
R the variance-covariance matrix for the repeated measures 
sig.level type one error 
power power 
alternative one- or two-sided test 
  
Table 5: The input arguments required in the “longpower” algorithm. 
 
After inserting the variance estimates’ values estimated by SPSS in the “longpower” 
algorithm [Appendix II], the algorithm calculated a sample size of 420. The R output 
was: 
 
Longitudinal linear model power calculation (Liu & Liang, 1997)  
 
              N = 419.3564 
              n = 209.6782, 209.6782 
          delta = 0.00477 
         sigma2 = 1 
      sig.level = 0.05 
          power = 0.8 
    alternative = two.sided 
 
 NOTE: N is total sample size and n is sample size in each group. 
 
An attempt to run the linear mixed model in R was made and variance estimates’ 
values were extracted. This time the “longpower” algorithm [Appendix III] calculated 
a sample size of 380. Although the sample size of 380 calculated completely by R is 
relatively close to the sample size of 420 calculated by SPSS and R but this fact 
shows that there exists a difference between SPSS and R using different algorithms to 
model a linear mixed model. 
 
Significance test of the variables 
 
The fixed and random coefficients of the variable TIME and coefficient of 
Log10_AD0 only as fixed turned out to be significant at the significance level of 5%. 
The rest of variables: RANGE, WOMAN, DIABETES and AGE were not significant 
at the significance level of 5%. 
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An attempt to run Log10_AD0 as a random effect in the linear mixed model was 
made hoping to obtain a better model. This attempt was not successful implying that 
there was no correlation in AD0 variable for the patients. 
 
Simulations   
                                                              
In order to evaluate the number 420 calculated by “longpower”, simulations of the 
model by a sample size of 2*210, number of measurements in time of 10 and two 
different fixed time slopes representing control and treatment groups were done. The 
parameter and variance estimates were retrieved from our original data of 211 placebo 
patients. A two-sample t-test showed a difference in means between these two groups 
at a statistical significance level of less than 0.1% [Appendix IV]. 
 
In SPSS the residuals for 2*210 patients were randomly spread with no 
heteroskedasticity and normally distributed. 
 
   
 
Figure 5: The residuals for simulated linear mixed model for 2*210 patients.  
 
By choosing the interaction term TREATMENT*TIME as random and fixed cross 
variable, the results in Table 6 and 7 were obtained for 2*210 patients in SPSS. As 
seen in the tables, there existed difference between control and treatment groups at 
significance level less than 0.1%. This means that 2*210 patients as a sample size is 
an appropriate sample size to start a similar study with.  
 
 
 
Table 6: The fixed cross effect estimates of the simulated linear mixed model for 
2*210 patients were statistically significant. Treatment=0 is for control and 
Treatment=1 is for the treatment group. 
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Table 7: The random variance estimates of the simulated linear mixed model for 
2*210 patients were statistically significant. 
 
To challenge the generated sample size of 2*210 by “longpower” another simulated 
linear mixed model was run with the same conditions in SPSS with only 2*105 
patients. The residuals for 2*105 patients were randomly spread with no 
heteroskedasticity and normally distributed. 
 
    
 
Figure 6: The residuals for simulated linear mixed model for 2*105 patients.  
 
TREATMENT*TIME as fixed and random cross variable gave fixed and random 
effects for 2*105 patients shown in Table 8 and Table 9. As seen, there again existed 
difference between control and treatment groups at significance level less than 0.1%. 
 
 
 
Table 8: The fixed cross effect estimates of the simulated linear mixed model for 
2*105 patients were statistically significant. Treatment=0 is for control and 
Treatment=1 is for the treatment group. 
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Table 9: The random variance estimates of the simulated linear mixed model for 
2*105 patients were statistically significant. 
 
Since there existed difference between control and treatment groups at significance 
level less than 0.1%, so even the sample size of 2*105 is acceptable to start a similar 
study with.  
 
Power calculations 
 
Power calculations both for the calculated sample size by “longpower”, 2*210 and our 
alternative sample size, 2*105 on simulated data were done [Appendices V-VIII]. 
 
Power calculations 
Sample size: 2*210 Sample size: 2*105 
N = 420.0002 
n = 210.0001, 210.0001 
delta = 0.00445 
sigma2 = 1 
sig.level = 0.05 
power = 0.7329034 
alternative = two.sided 
N = 209.9914 
n = 104.9957, 104.9957 
delta = 0.00456 
sigma2 = 1 
sig.level = 0.05 
power = 0.60751 
alternative = two.sided 
 
Table 10: Power calculations of sample sizes 2*210 and 2*105 are crucial to choose 
an appropriate sample size. 
 
These findings showed how a powerful tool “longpower” is to calculate sample size 
and power and its ability to predict an appropriate sample size for data before start of 
an experiment. A desired sample size is followed by a desired power for an 
experiment. 
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Discussion 
 
Correlation in scientific data occurs frequently. Longitudinal data is a perfect example 
of correlated data. The statistical model, the linear mixed model is designed to study 
such data to give correct estimates for the fixed variables and variance estimates for 
the random variables. Unfortunately, the correlations in this work were assumed to be 
zero since the data was collected in non-equidistant time periods. The covariance 
structure for the linear mixed model was chosen accordingly namely no correlation 
between measurements for a patient. The longitudinal data was treated as an 
independent sample in this work. 
 
Abdominal aortic aneurysm (AAA) is especially important to study due to its high 
mortality rate among people older than 65. Gender, ethnicity and smoking are the 
biggest risk factors. Ruptured abdominal aortic aneurysms (AAAs) cause 15,000 
deaths per year in US and 12,000 in UK [9, 10]. Since patients with risk factors are 
screened frequently by ultrasound in order to have control over the growth of the 
aneurysm, makes this group of patients interesting for mixed model analysis.  
 
Another major issue to consider in such analyses is the assessment of the sample size. 
Sample size calculation is needed prior to the design of the study which makes 
algorithms created for this purpose of great importance. 
 
The fact that in this work, 420 patients as a sample size was calculated by the 
“longpower” package in R using a linear mixed model showed the efficiency of this 
algorithm to calculate a sample size with a desired power prior to an experiment.  
 
A major limitation in this work was the fact that only a data of placebo patients was 
provided. Data of treatment patients lacked which forced us to make a lot of 
assumptions in the study. E.g. correlation between random intercept and random slope 
for the treatment group was assumed to be 0 and the number of measurements for this 
group was assumed to be 10. In addition the improvement of the treatment group was 
simulated by reduction of the slope by 20%. Indeed, with a data of treatment patients 
much more accurate calculations could be done.  
 
Although there were many variables registered in this study, the variables WHITE and 
SMOKER were missing. These variables are of great importance for emergence and 
development of abdominal aortic aneurysm [9, 10].  
 
The calculated sample size by “longpower” was 420. Simulations of the model for 
control and treatment groups with sample sizes of 2*210 and 2*105 gave a difference 
in means at a statistical significance level of less than 0.1% in two-sample t-tests. In 
addition, for both simulations the fixed parameter estimates and the random variance 
estimates were statistically significant when run as linear mixed models. This fact 
showed that both sample sizes are acceptable until power calculations were done for 
those sample sizes. The power calculations indicated that a sample size of 2*210 gave 
much higher power than a sample size of 2*105. 
 
Despite “longpower” being a very powerful tool, it needs at least one more 
improvement. Namely, one cannot insert in “longpower” function correlations 
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between different measurements when the measurements are non-equidistant. 
Measurements close to each other are more correlated than measurements far from 
each other. Although “longpower” has undergone many improvements since its 
emergence in 1997 but more improvements are clearly expected. Its efficiency to 
calculate sample size and power will keep it practical for researchers in the near 
future.  
 
It is important to remember that the results obtained in this work are only 
computations. These calculations need to be further examined and verified by more 
clinical experiments and statistical computations.  
 
Future challenges  
 
There is no doubt that sample size calculations and algorithms created for that purpose 
will continue to be of current interest. More and more of these algorithms will be 
programmed by statisticians and evaluated by clinical researchers. 
 
The next step of studying abdominal aortic aneurysm is to include as many variables 
as possible which can be suspected to play a role for the emergence and development 
of this affliction. Indeed, bigger sample groups of both placebo and treatment patients 
are needed despite the cost of ultrasound screenings.   
 
The study of abdominal aortic aneurysm will continue to be on the general agenda for 
the scientists in the future due to aging populations in the world. This affliction will 
affect millions of people in the future and necessary measures need to be taken.  
 
In the light of this fact, advanced statistician algorithms, software and reasonably less 
costly screening apparatuses need to be developed and invented. These findings will 
not only help us to understand the nature of abdominal aortic aneurysm but will also 
help us to discover new drugs and treatments for AAA patients and other similar 
diseases and thereby save lives. 
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Patients and Methods 
 
Data 
 
The dependant variable (AD) was the aneurysm diameter (measured in mm) and the 
studied independent variables were: 
 
Variable Description 
AD0 Aneurysm diameter at baseline (mm) 
AD – AD0 Adjusted aneurysm diameter (mm) 
RANGE 25<=AD0<35 == 0 
35<=AD0<45 == 1 
45<=AD0<55 == 2 
         AD0=>55 == 3 
TIME  Measurements (year) 
WOMAN Woman == 1, Man == 0 
DIABETES Yes == 1, No == 0 
AGE  
  
Table 11: The variables provided in the study of abdominal aortic aneurysm and the 
response variable (AD). 
 
AD, AD0, ADJUSTED_AD, TIME and AGE were handled as continuous data 
whereas RANGE, WOMAN and DIABETES as categorical data. No missing values 
were encountered.    
 
Software 
SPSS 
 
SPSS (originally, Statistical Package for the Social Sciences) is a computer program 
used for many different applications, among others survey authoring and deployment, 
data mining, text analytics and statistical analysis. SPSS version 20 was used in this 
work to analyze a linear mixed model and to draw respective diagrams. This is 
powerful software that can do many things and works perfectly with any kind of 
pharmaceutical data.  
 
Unfortunately, SPSS has a poor export function for texts like tables as a graphic 
format. It made me first save my tables in other software to be able to save them as 
graphics. Another limitation was SPSS’ inability to plot a linear mixed model. 
R 
 
R is a programming language and software environment for statistical analysis and 
graphics. Most users agree that R is much more powerful than other popular statistical 
packages, such as SAS, SPSS and Stata.  
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R is an extensive programming tool partly because of its user-created packages. This 
feature makes it possible to do specialized statistical techniques, graphical devices, 
import/export capabilities, reporting tools and so much more. Importantly, it was 
possible to plot a linear mixed model in R which makes it easier for the researcher to 
comprehend and visualize the studied model.   
 
R version 3.0.0 was used in this work to do the statistical calculations and 
simulations. Especially the “longpower” package written by Liu and Liang (1997) 
was used for our pharmaceutical data.   
 
Statistical analyses 
Linear mixed model 
 
A linear mixed model is a linear statistical model containing both fixed and random 
effects that allows for correlation between measurements. This model was used in this 
work because there were mixed effects in the data due to repeated screenings on the 
same person during time intervals. 
 
The model was run in SPSS choosing the logarithm of aneurysm diameter 
(Log10_AD) as dependent variable, the logarithm of aneurysm diameter at baseline 
(Log10_AD0) as fixed and time (TIME) as both fixed and random variable. 
 
The covariance structure was chosen in accordance to Littell et al. (2000, [4]). The 
covariance structure “Variance components” in SPSS was chosen since our 
pharmaceutical data lacked a repeated variable and no correlation between the non-
equidistant measurements was assumed. To express it statistically: 
 
Cov(Yijk, Yijl) = σ
2
b = 0    ,    k ≠ l 
 
Var(Yijk) = Cov(Yijk, Yijk) = σ
2
b + σ
2
w = 0 + σ
2
w = σ
2
w    
 
i = individual 
j = time 
k, l = measurement  
σ2b = between-individual variance 
σ2w = within-individual variance 
 
Variance Components: 
[
 
 
 
 
  
     
     
     
     
      
 ]
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Statistical power 
 
The power of a statistical test is the probability that the test will reject the null 
hypothesis when the null hypothesis is false i.e. the probability of not committing a 
Type II error. Since the probability of a Type II error is referred as β, the power is 
referred as 1 – β. 
 
Power analysis can be used to calculate the minimum sample size required so that one 
can likely detect an effect of a given size. Power analysis can also be used to calculate 
the minimum effect size that is likely to be detected in a study using a given sample 
size. 
 
A simple example: Assume 
{
        
        
 
 
and true value of the mean μ = 52, sample size n = 10 and Type II error β = 0.264. 
 
So the power is: 1 – β = 1 – 0.264 = 0.736 = 73.6% when μ = 52.   
 
Power is a measure of sensitivity of a statistical test and in this example it means that 
if the true value of mean is really 52, this test will correctly reject the null hypothesis 
73.6% of the time. If this value of power is judged to be too low, an increase in 
sample size n can be considered. 
Two-sample t-test 
 
This test was used to compare the means of two simulated control and treatment 
groups with the same sample size and equal variances. The following hypotheses were 
considered: 
 
{
     ̅    ̅   
     ̅    ̅   
   
 
The t-statistic to test if the means are different is:         
 ̅   ̅ 
√    
      
    
 
 ̅  = mean of each group  
   
 
 = variance of each group 
i = 1, 2 
2n – 2 = degrees of freedom for this test 
n = sample size 
The denominator of t is the standard error of the difference between two means. 
Finally, the null hypothesis is rejected if tobs > tcritical. 
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Appendix I  
(Using SPSS and R) 
 
#Program: Calculating delta (difference of slopes of control and  
#treatment patients) with a given effect (%20) for an abdominal  
#aortic aneurysm data. Delta is an argument in "longpower". 
#All parameter estimates were retrieved using SPSS. 
#Author: Eric Markarian 
#Date: 01.04.2013 
 
#These estimates were retrieved after running linear mixed model in SPSS 
fixed.intercept  <- 0.023364 #Fixed intercept coefficient estimate   
fixed.time  <- 0.023846 #Fixed time slope coefficient estimate 
fixed.log10AD0 <- 0.983406 #Fixed log10AD0 slope coefficient estimate 
LOG10AD0  <- 1.5702 #Mean of log10AD0 
n   <- 2*1  #One control and one treatment patient 
p   <- 10  #Number of measurements 
 
#Create a log10AD matrix and define a simple model 
log10AD <- matrix(nrow=n, ncol=p)  
for(i in 1:n) { 
 if (i > n/2) 
  fixed.time <- 0.8 * fixed.time  #For treatment patient 
 for(t in 1:p) { 
  log10AD[i, t] <- fixed.intercept +  
   fixed.log10AD0*LOG10AD0 + fixed.time*t  
 } 
} 
 
#Split log10AD to control and treatment patients for plotting 
log10AD.control <- log10AD[1:(n/2),] 
log10AD.treatment <- log10AD[((n/2)+1):n,] 
 
#Create time variable and time matrix 
time  <- seq(0, 9, 1) 
time.matrix <- matrix(time, nrow=n/2, ncol=p, byrow = TRUE) 
 
#Create a device with specific size with place for 1 figure 
dev.new(width=60, height=32) 
par(mfrow = c(1,1)) 
 
#Plot log10AD.control and log10AD.treatment vs time.matrix 
plot(time.matrix, log10AD.control,  
 xlim=c(-0.1,10), ylim=c(1.5,2),  
 xlab="Time", ylab="Log10 AD", pch=19) 
par(new=TRUE) 
plot(time.matrix, log10AD.treatment, col="green",  
 xlim=c(-0.1,10), ylim=c(1.5,2),   
 xlab="Time", ylab="Log10 AD", pch=19) 
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abline(h = 1.74, col="red") #Rupture line 
 
log10AD.control.line <- lm(log10AD.control ~ time) 
summary(log10AD.control.line) #Gave control slope 0.02385 
 
log10AD.treatment.line <- lm(log10AD.treatment ~ time) 
summary(log10AD.treatment.line) #Gave treatment slope 0.01908    
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Appendix II 
(Using SPSS and R) 
 
#Program: Calculating sample size with a given effect (%20) for an abdominal  
#aortic aneurysm data based on the formula of Liu and Liang (1997) 
#using "longpower" package in R.  
#All variance estimates were retrieved using SPSS. 
#Author: Eric Markarian 
#Date: 01.04.2013 
 
library(longpower) 
 
#These estimates were retrieved using SPSS 
sigma2.i  <- 0.000130      #Variance of random intercept   
sigma2.s  <- 0.000300      #Variance of random slope 
sigma2.e  <- 0.000323      #Residual variance 
 
#Covariance of slope and intercept 
#Correlation between random intercept and random slope was assumed to be 0 
covariance.s.i <- 0*sqrt(sigma2.i)*sqrt(sigma2.s)     
 
#t is number of measurements for treatment group 
#10 measurements for treatment group were assumed here 
t = seq(0, 9, 1)    
n = length(t) 
 
#Covaiance structure 
covariance.t <- function(t1, t2, sigma2.i, sigma2.s, covariance.s.i){ 
 sigma2.i + t1*t2*sigma2.s + (t1+t2)*covariance.s.i} 
R = outer(t, t, function(x,y){covariance.t(x, y,  
 sigma2.i, sigma2.s, covariance.s.i)}) 
R = R + diag(sigma2.e, n, n) 
 
#A covariate vector associated with the parameter of interest 
u = list(u1 = t, u2 = rep(0,n)) 
 
#A covariate vector associated with the nuisance parameter 
v = list(v1 = cbind(1,1,rep(0,n)), v2 = cbind(1,0,t)) 
 
#The slope values were calculated in Appendix I 
control.slope  <- 0.02385 
treatment.slope <- 0.01908 
 
#Run the liu.liang.linear.power function to obtain the sample size 
print(liu.liang.linear.power(delta=control.slope-treatment.slope, u=u,  
 v=v, R=R, sig.level=0.05, power=0.8, alternative="two.sided"), "\n") 
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Appendix III  
(Using only R) 
 
#Program: Calculating sample size with a given effect (%20) for an abdominal  
#aortic aneurysm data based on the formula of Liu and Liang (1997) 
#using "longpower" package in R.  
#The variance estimates were retrieved after printing the R model below. 
#Author: Eric Markarian 
#Date: 01.04.2013 
 
library(xlsx) 
library(longpower) 
library(lme4) 
library(languageR) 
 
fil <- read.xlsx("AAA.xlsx", 1)   #Read a .xlsx file's 1st sheet 
 
#Define the linear mixed model with default Variance-Covariance structure (no 
#correlation between measurements for the same patient)   
model <- lmer(fil$LOG10_AD ~ 1 + fil$LOG10_AD0 + fil$TIME +  
 (1 + fil$TIME | fil$SUBJECT), REML = FALSE) 
print(model) 
 
#Calculate the residuals and the fitted values 
residuals  <- resid(model) 
fitted.values  <- fitted(model) 
 
#Create a device with specific size with place for 2 figures 
dev.new(width=40, height=16) 
par(mfrow = c(1,2)) 
 
#Plot fitted values of the model vs residuals 
plot(fitted.values, residuals,  
   xlab="Fitted values of Log10 AD", 
   ylab="Residuals", main="Figure 1", pch=19)  
abline(h = 0) 
 
#Create a histogram over the residuals 
hist(residuals, density=20, breaks=20, prob=TRUE,  
 xlab="Residuals of Log10 AD", ylim=c(0, 35), main="Figure 2")  
curve(dnorm(x, mean=mean(x),sd=sd(x)),  
      col="blue", lwd=2, add=TRUE)   
 
#Inserted estimates are from the output of the model above 
sigma2.i   <- 0.00012363 #Variance of random intercept 
sigma2.s   <- 0.00027201 #Variance of random slope 
sigma2.e   <- 0.00031904 #Residual variance 
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#Covariance of slope and intercept 
#Correlation between random intercept and random slope was assumed to be 0 
covariance.s.i <- 0*sqrt(sigma2.i)*sqrt(sigma2.s)     
 
#t is number of measurements for treatment group 
#10 measurements for treatment group were assumed here 
t = seq(0, 9, 1)    
n = length(t) 
 
#Covaiance structure 
covariance.t <- function(t1, t2, sigma2.i, sigma2.s, covariance.s.i){ 
 sigma2.i + t1*t2*sigma2.s + (t1+t2)*covariance.s.i} 
R = outer(t, t, function(x,y){covariance.t(x, y,  
 sigma2.i, sigma2.s, covariance.s.i)}) 
R = R + diag(sigma2.e, n, n) 
 
#A covariate vector associated with the parameter of interest (random var?) 
u = list(u1 = t, u2 = rep(0,n)) 
 
#A covariate vector associated with the nuisance parameter (fixed var?) 
v = list(v1 = cbind(1,1,rep(0,n)), v2 = cbind(1,0,t)) 
 
#The slope values were calculated in Appendix I 
control.slope  <- 0.02385 
treatment.slope <- 0.01908 
 
#Run the liu.liang.linear.power function to obtain the sample size 
print(liu.liang.linear.power(delta=control.slope-treatment.slope, u=u,  
 v=v, R=R, sig.level=0.05, power=0.8, alternative="two.sided"), "\n") 
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Appendix IV 
(Using SPSS and R) 
 
#Program: Simulations of a linear mixed model with a given sample size with  
#two different slopes of time for an abdominal aortic aneurysm data.  
#Finally, a two-sample t-test compares these two simulations. 
#All parameter and variance estimates were retrieved using SPSS.  
#Author: Eric Markarian 
#Date: 01.04.2013         
 
#The parameter and variance estimates' values are inserted after running the 
#linear mixed model in SPSS. The number of patients is calculated by  
#"longpower" package in R. 
fixed.intercept  <- 0.023364 #Fixed intercept coefficient estimate   
fixed.time  <- 0.023846 #Fixed time slope coefficient estimate 
fixed.log10AD0 <- 0.983406 #Fixed log10AD0 slope coefficient estimate   
sigma.i  <- sqrt(0.000130) #Standard deviation of intercept 
sigma.s  <- sqrt(0.000300) #Standard deviation of time slope  
sigma.e  <- sqrt(0.000323) #Standard deviation of standard error 
n   <- 2*105 #Number of control and treatment patients 
p   <- 10  #Number of measurements 
 
#Create a log10AD matrix and define the simulation model 
log10AD <- matrix(nrow=n, ncol=p)  
for(i in 1:n) { 
 random.intercept <- rnorm(1, 0, sigma.i) #Random intercept 
 random.time  <- rnorm(1, 0, sigma.s) #Random time 
 if (i > n/2) 
  fixed.time <- 0.8 * fixed.time  #For treatment group 
 for(t in 1:p) { 
  log10AD[i, t] <- fixed.intercept + random.intercept +  
   fixed.log10AD0 + (fixed.time + random.time)*t +  
   rnorm(1, 0, sigma.e) #Random error 
 } 
 if (i > n/2) 
  fixed.time <- fixed.time / 0.8  #Restore fixed.time 
} 
 
#Split log10AD to control and treatment groups for plotting 
log10AD.control <- log10AD[1:(n/2),] 
log10AD.treatment <- log10AD[((n/2)+1):n,] 
 
#Create time variable and time matrix 
time  <- seq(0, 9, 1) 
time.matrix <- matrix(time, nrow=n/2, ncol=p, byrow = TRUE) 
 
#Create a device with specific size with place for 1 figure 
dev.new(width=60, height=32) 
par(mfrow = c(1,1)) 
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#Plot log10AD.control and log10AD.treatment vs time.matrix 
plot(time.matrix, log10AD.control,  
 xlim=c(-0.1,10), ylim=c(0,2.5),  
 xlab="Time", ylab="Simulated Log10 AD", pch=19) 
par(new=TRUE) 
plot(time.matrix, log10AD.treatment, col="green",  
 xlim=c(-0.1,10), ylim=c(0,2.5),   
 xlab="Time", ylab="Simulated Log10 AD", pch=19) 
abline(h = 1.74, col="red") #Rupture line 
 
#Two-sample t-test for comparing the means of the control and the 
#treatment groups. 
print(t.test(log10AD.control, log10AD.treatment, alternative="two.sided",  
 var.equal=TRUE)) 
 
#Write the output to a file 
sink("HelpFile.txt") 
array(t(log10AD), c(n*p,1)) 
sink() 
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Appendix V 
(Using SPSS and R) 
 
#Program: Calculating delta (difference of slopes of control and treatment  
#patients) with a given effect (%20) for a simulated abdominal aortic aneurysm  
#data à 2*210 patients. Delta is an argument in "longpower". 
#All parameter estimates were retrieved using SPSS. 
#Author: Eric Markarian 
#Date: 01.04.2013 
 
#These estimates were retrieved after running linear mixed model in SPSS 
fixed.intercept  <- 1.006002 #Fixed intercept coefficient estimate   
fixed.time.control <- 0.022251 #Fixed time*control coefficient estimate 
fixed.time.treatment <- 0.018790 #Fixed time*treatment coefficient estimate 
n   <- 2*1  #One control and one treatment patient 
p   <- 10  #Number of measurements 
 
#Create a log10AD matrix and define a simple model 
log10AD <- matrix(nrow=n, ncol=p)  
for(i in 1:n) { 
 if (i > n/2) 
  fixed.time.control <- 0.8 * fixed.time.control #For treatment patient 
 for(t in 1:p) { 
  log10AD[i, t] <- fixed.intercept +  
   fixed.time.control*t  
 } 
} 
 
#Split log10AD to control and treatment patients for plotting 
log10AD.control <- log10AD[1:(n/2),] 
log10AD.treatment <- log10AD[((n/2)+1):n,] 
 
#Create time variable and time matrix 
time  <- seq(0, 9, 1) 
time.matrix <- matrix(time, nrow=n/2, ncol=p, byrow = TRUE) 
 
#Create a device with specific size with place for 1 figure 
dev.new(width=60, height=32) 
par(mfrow = c(1,1)) 
 
#Plot log10AD.control and log10AD.treatment vs time.matrix 
plot(time.matrix, log10AD.control,  
 xlim=c(-0.1,10), ylim=c(1,2),  
 xlab="Time", ylab="Log10 AD", pch=19) 
par(new=TRUE) 
plot(time.matrix, log10AD.treatment, col="green",  
 xlim=c(-0.1,10), ylim=c(1,2),   
 xlab="Time", ylab="Log10 AD", pch=19) 
abline(h = 1.74, col="red") #Rupture line 
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log10AD.control.line <- lm(log10AD.control ~ time) 
summary(log10AD.control.line)  #Gave control slope 0.02225 
 
log10AD.treatment.line <- lm(log10AD.treatment ~ time) 
summary(log10AD.treatment.line)  #Gave treatment slope 0.0178     
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Appendix VI 
(Using SPSS and R) 
 
#Program: Calculating power with a given effect (%20) for a simulated  
#abdominal aortic aneurysm data à 2*210 patients based on the formula  
#of Liu and Liang (1997) using "longpower" package in R.  
#All variance estimates were retrieved using SPSS. 
#Author: Eric Markarian 
#Date: 01.04.2013 
 
library(longpower) 
 
#These estimates were retrieved using SPSS 
sigma2.i  <- 0.000104      #Variance of random intercept   
sigma2.s  <- 0.000308      #Variance of random slope 
sigma2.e  <- 0.000329      #Residual variance 
 
#Covariance of slope and intercept 
#Correlation between random intercept and random slope was assumed to be 0 
covariance.s.i <- 0*sqrt(sigma2.i)*sqrt(sigma2.s)     
 
#t is number of measurements for treatment group 
#10 measurements for treatment group were assumed here 
t = seq(0, 9, 1)    
n = length(t) 
 
#Covaiance structure 
covariance.t <- function(t1, t2, sigma2.i, sigma2.s, covariance.s.i){ 
 sigma2.i + t1*t2*sigma2.s + (t1+t2)*covariance.s.i} 
R = outer(t, t, function(x,y){covariance.t(x, y,  
 sigma2.i, sigma2.s, covariance.s.i)}) 
R = R + diag(sigma2.e, n, n) 
 
#A covariate vector associated with the parameter of interest 
u = list(u1 = t, u2 = rep(0,n)) 
 
#A covariate vector associated with the nuisance parameter 
v = list(v1 = cbind(1,1,rep(0,n)), v2 = cbind(1,0,t)) 
 
#The slope values were calculated in Appendix V 
control.slope  <- 0.02225 
treatment.slope <- 0.0178 
 
#Run the liu.liang.linear.power function to obtain the power 
print(liu.liang.linear.power(N=2*210, delta=control.slope-treatment.slope, u=u,  
 v=v, R=R, sig.level=0.05, alternative="two.sided"), "\n") 
 
 
 
